Assembly Biosciences Inc Revenue Growth Rates (ASMB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Assembly Biosciences Inc   (NASDAQ: ASMB)
 

ASMB's Revenue Growth by Quarter and Year

Assembly Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ASMB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 13.37
1st Quarter March 8.21
FY 21.58

ASMBs Annual Revenue
Assembly Biosciences Inc 's Revenue in the fiscal year 2025 $ 72.30 millions
Assembly Biosciences Inc 's Revenue in the fiscal year 2024 $ 28.52 millions
Assembly Biosciences Inc 's Revenue in the fiscal year 2023 $ 7.16 millions
Assembly Biosciences Inc 's Revenue in the fiscal year 2022 $ 0.00 millions
Assembly Biosciences Inc 's Revenue in the fiscal year 2021 $ 6.25 millions




ASMB Revenue second quarter 2026 Y/Y Growth Comment
Assembly Biosciences Inc reported Revenue improvement of 38.88% year on year in the second quarter 2026, to $ 13.37 millions, this is lower than Assembly Biosciences Inc 's recent average Revenue surge of 105.95%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue growth. While Assembly Biosciences Inc ' s Revenue rise of 38.88% ranks overall at the positon no. 582 in the second quarter 2026.


ASMB Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 477.04 % 2.79 % -
3rd Quarter September - 57.52 % - -
2nd Quarter June 38.88 % 12.9 % - -
1st Quarter March -12.85 % 62.69 % - -
FY   - 153.45 % 298.46 % -

Financial Statements
Assembly Biosciences Inc 's second quarter 2026 Revenue $ 13.37 millions ASMB's Income Statement
Assembly Biosciences Inc 's second quarter 2025 Revenue $ 9.63 millions Quarterly ASMB's Income Statement


ASMB Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 293.61 % 7.45 % -
3rd Quarter September - 12.05 % -19.7 % -
2nd Quarter June 62.9 % 2.23 % 47.32 % -
1st Quarter March -80.67 % 27.99 % -19.13 % -
FY (Year on Year)   - 153.45 % 298.46 % -


Back to ASMB Growth rate Comparisons >> Back to ASMB Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #140
Overall #582

Revenue Y/Y Growth Statistics
High Average Low
1178.44 % 105.95 % -100 %
(Sep 30 2020)   (Sep 30 2019)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #140
Overall #582
Revenue Y/Y Growth Statistics
High Average Low
1178.44 % 105.95 % -100 %
(Sep 30 2020)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Assembly Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
864.86 % 44.78 % -100 %
(Jun 30 2020)  


ASMB's II. Quarter Q/Q Revenue Comment
Assembly Biosciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 62.9%, to $ 13.37 millions, from $8.21 millions in the first quarter.
ASMB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Assembly Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 193.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #57
Overall #193
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #57
Overall #193
Revenue Q/Q Growth Statistics
High Average Low
864.86 % 44.78 % -100 %
(Jun 30 2020)  


ASMB's II. Quarter Q/Q Revenue Comment
Assembly Biosciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 62.9%, to $ 13.37 millions, from $8.21 millions in the first quarter.
ASMB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Assembly Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 193.


Assembly Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 74.85 $ 71.10 $ 72.30 $ 37.19 $ 33.25
Y / Y Revenue Growth (TTM) 125.12 % 121.11 % 153.52 % 31.3 % -
Year on Year Revenue Growth Overall Ranking # 532 # 309 # 315 # 359 # 0
Seqeuential Revenue Change (TTM) 5.27 % -1.67 % 94.41 % 11.86 % 3.4 %
Seq. Revenue Growth (TTM) Overall Ranking # 2248 # 832 # 1937 # 1996 # 1593


Cumulative Revenue growth Comment
Although Assembly Biosciences Inc 's Annual Revenue growth year on year were below company's average 127.58% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 125.12% year on year, from 121.11% in Mar 31 2026.

In the Healthcare sector 124 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 309 to 532.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 125
Overall # 532

Revenue TTM Y/Y Growth Statistics
High Average Low
454.78 %
 127.58 %
3.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 328
S&P 500 # 2248
Cumulative Revenue growth Comment
Although Assembly Biosciences Inc 's Annual Revenue growth year on year were below company's average 127.58% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 125.12% year on year, from 121.11% in Mar 31 2026.

In the Healthcare sector 124 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 309 to 532.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 125
Overall # 532

Revenue TTM Y/Y Growth Statistics
High Average Low
454.78 %
127.58 %
3.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 328
S&P 500 # 2248




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ASMB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions


About Assembly Biosciences Inc Revenue Growth Rates (ASMB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Assembly Biosciences Inc (CIK 1426800).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-349236
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Assembly Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.